Colorectal Cancer
Conditions
Keywords
Third-line
Brief summary
The current study is to investigate the safety and efficacy of fruquintinib combined with HAIC in patients with advanced colorectal liver metastases who have failed second-line systemic standard treatment, in order to provide more survival opportunities for the second progression of advanced colorectal liver metastases.
Detailed description
Among Chinese colorectal cancer patients, 43.8% had metastasis at the time of diagnosis, of which liver metastasis accounted for 51.5%. In addition, it was reported that 10%-25% of patients developed liver metastasis after radical resection of colorectal cancer, and more than two-thirds of colorectal patients eventually developed liver metastasis. Colorectal liver metastasis was reported to be the most important cause of death in colorectal cancer patients.The median survival time of untreated liver metastases was only 6.9 months, and the 5-year survival rate of unresectable patients was less than 5%, and for unresectable colorectal liver metastasis, the median survival time could reach 30.9 months after comprehensive treatment. Fruquintinib, a VEGFR 1/2/3 inhibitor, is one of the standard 3rd-line therapy for colorectal cancer, which has already been approved and marketed in China. In phase III FRESCO study, liver metastases subgroup showed that the median OS of fruquintinib group was 8.61 months, which was 2.63 months longer than that of control group, reducing death risk by 41%, with statistically significant P value. Patients with large tumor burden mainly caused by liver metastasis and with insignificant or refractory response to drug therapy, or patients who cannot tolerate systemic therapy, can be combined with transcatheter arterial chemoembolization (HAI) or transcatheter arterial chemoembolization (TACE) at appropriate time, which helps to prolong the progression-free time and overall survival. The current study is to investigate the safety and efficacy of fruquintinib combined with HAIC in patients with advanced colorectal liver metastases who have failed second-line systemic standard treatment, in order to provide more survival opportunities for the second progression of advanced colorectal liver metastases.
Interventions
DRUGFruquintinib
Fruquintinib
DRUGHAIC
HAIC
Sponsors
Hutchison Medipharma Limited
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Fully understand the study and voluntarily sign the informed consent form; 2. Age ≥ 18 years; 3. Patients with unresectable colorectal liver metastases who have failed standard second-line systemic therapy, who have not previously received HAIC therapy, and have not received third-line standard targeted agents (regorafenib or fruquintinib or trifluridine tipiracil (TAS-102); 4. Definition of liver metastases: at least 1 measurable liver metastasis lesion (based on RECIST 1.1); if the liver metastases are single, the tumor is \> 5 cm; if multiple tumors, it needs to be greater than or equal to 4, of which at least 1 exceeds 3 cm; 5. PFS \> 4 months from last dose of oxaliplatin with FOLFOX regimen 6. Child-Pugh classification of liver function: A; 7. ECOG performance status 0-1, and no deterioration within 7 days; 8. BMI ≥ 18; 9. Expected survival ≥ 3 months; 10. Vital organs function in accordance with the following requirements (any blood components and cell growth factors are not allowed within 14 days before enrollment): * Absolute neutrophil count ≥ 1.5 × 109/L and white blood cells ≥ 4.0 × 109/L; * Platelets ≥ 100 × 109/L; * Hemoglobin ≥ 90 g/L; * Total bilirubin TBIL ≤ 1.5 times ULN; * ALT and AST ≤ 5 times ULN; * Urea nitrogen/urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL/min); * Left ventricular ejection fraction (LVEF) ≥ 50%; * Fridericia-corrected QT interval (QTcF) \< 470 milliseconds. * INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN. 11. women of childbearing age need to take effective contraceptive measures; 12. good compliance and cooperation with follow-up.
Exclusion criteria
1. Unable to comply with the study protocol or study procedures; 2. Pregnant or breastfeeding women; 3. Any factor affecting oral administration; 4. Evidence of central nervous system metastases; 5. Concurrent with any of the following: uncontrolled hypertension, coronary artery disease, arrhythmia, and heart failure; 6. Alcohol or drug abuse within 4 weeks after the last clinical trial; 7. Previous VEGFR inhibition therapy; 8. Uncontrolled severe concurrent infection resulting in disability; 9. Proteinuria ≥ 2 + (1.0 g/24 h); 10. Evidence or history of bleeding tendency within 2 months prior to enrollment, regardless of seriousness; 11. Arterial/venous thromboembolic events, such as cerebrovascular accidents (including transient ischemic attack), within 12 months before the first treatment; 12. Acute myocardial infarction, acute coronary syndrome or CABG within 6 months before the first treatment; 13. Fractures or wounds that have not been cured for a long time; 14. coagulopathy, bleeding tendency or receiving anticoagulant therapy; 15. Inactivated vaccines within 4 weeks prior to enrollment or possible during the study; 16. Patients with other malignant tumors within 5 years before enrollment, except for basal cell or squamous cell carcinoma of the skin after radical resection, or cervical carcinoma in situ; 17. Active autoimmune diseases or history of autoimmune diseases within 4 weeks before enrollment; 18. Previous allogeneic bone marrow transplantation or organ transplantation; 19. Subjects who are allergic to the study drug or any of its adjuvant preparations; 20. Electrolyte abnormalities judged clinically significant by the investigator; 21. Known human immunodeficiency virus (HIV) infection. Known history of clinically significant liver disease, including viral hepatitis \[known hepatitis B virus (HBV) carriers must have excluded active HBV infection, ie, positive HBV DNA (\> 1 × 104 copies/mL or \> 2000 IU/mL); known hepatitis C virus (HCV) infection and positive HCV RNA (\> 1 × 103 copies/mL); 22. Unresolved toxicities above CTCAE v5.0 grade 1 due to any prior anticancer therapy, excluding alopecia, lymphopenia, and oxaliplatin-induced neurotoxicity ≤ grade 2; 23. Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 28 days before enrollment; 24. with brain metastases, or with severe malignant pleural effusion and ascites; 25. Any other diseases, clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the investigator 's judgment, there is reason to suspect that the patient has a disease or condition that is not suitable for the use of the study drug (such as having seizures and requiring treatment), or will affect the interpretation of the study results, or put the patient at high risk; 26. Patients who are considered unsuitable for inclusion in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | from randomization until death due to any cause, assessed up to 2 year | every two months after end of treatment (EOT) observation period at 30 days after the last medication every two months after end of treatment (EOT) observation period at 30 days after the last medication every two months after end of treatment (EOT) observation period at 30 days after the last medication |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress-free Survival | from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year | Tumor assessment will be performed using radiography method every 8 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1 |
| Objective Response Rate | from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year | Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1 |
| Safety and tolerance evaluated by incidence, severity and outcomes of AEs | from first dose to within 30 days after the last dose | Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0. |
Countries
China
Outcome results
None listed